Analysts Issue Forecasts for Kodiak Sciences Q3 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD) – Equities researchers at Zacks Research increased their Q3 2025 earnings estimates for shares of Kodiak Sciences in a research report issued on Tuesday, October 22nd. Zacks Research analyst R. Department now forecasts that the company will post earnings of ($1.10) per share for the quarter, up from their previous estimate of ($1.13). The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.52) per share. Zacks Research also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($1.17) EPS, FY2025 earnings at ($4.00) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($1.04) EPS and FY2026 earnings at ($3.82) EPS.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.01.

Separately, HC Wainwright restated a “neutral” rating and set a $3.00 price target on shares of Kodiak Sciences in a report on Tuesday, September 24th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $5.00.

Kodiak Sciences Trading Down 3.1 %

NASDAQ:KOD opened at $3.43 on Friday. The firm has a market capitalization of $180.20 million, a PE ratio of -0.77 and a beta of 2.34. Kodiak Sciences has a 1 year low of $1.37 and a 1 year high of $7.77. The firm’s fifty day simple moving average is $2.73 and its 200 day simple moving average is $2.96.

Hedge Funds Weigh In On Kodiak Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Diversified Trust Co acquired a new stake in Kodiak Sciences in the 1st quarter worth $83,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Kodiak Sciences during the first quarter worth about $68,000. RIA Advisory Group LLC bought a new position in Kodiak Sciences during the first quarter valued at about $489,000. Susquehanna Fundamental Investments LLC acquired a new position in Kodiak Sciences in the 1st quarter valued at approximately $236,000. Finally, Sei Investments Co. bought a new stake in shares of Kodiak Sciences in the 1st quarter worth approximately $595,000. Institutional investors own 89.06% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.